Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
NCT Number: NCT06854406
The purpose of this study is to evaluate the effect of varenicline on rectal sensation, based on ascending method of limits and on graded rapid phasic distensions in participants with non-constipation IBS and chronic abdominal pain.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Rochester, Minnesota, 55905, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 12/27/2024. Questions regarding updates should be directed to the study team contact.
Initial, 0.5 mg orally once daily for 3 days, then 0.5 mg every 12 hours on days 4 through 7, and then 1 mg in morning of day 8. Medication is taken after eating and with a full glass of water.
Time frame: Comparison on day 8 of vareniciline treatment compared to baseline
Pressure-volume relationship of rectum during balloon distension
Time frame: Comparison on day 8 of vareniciline treatment compared to baseline
Report of rectal sensation during balloon distension 0-44mmHg
Time frame: Comparison on day 8 of vareniciline treatment compared to baseline
Report of rectal sensation during balloon distensions
Time frame: 8 days
Safety/adverse effects during administration of varenicicline
Mayo Clinic
Other
Varenicline in the Treatment of Visceral Sensation: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06221111
Colonic Diseases, Colonic Diseases, Functional
Rochester, Minnesota, United States
View Trial DetailsNCT02973542
Colonic Diseases, Colonic Diseases, Functional
Clermont-Ferrand, France
View Trial DetailsNCT03806127
Colonic Diseases, Colonic Diseases, Functional
Birmingham, Alabama, United States
View Trial DetailsNCT03332537
Colonic Diseases, Colonic Diseases, Functional
Farmington, Connecticut, United States
View Trial Details